Aging and frailty Not Applicable
Conditions
Interventions
The study was aimed to evaluate the prevalence of endocrine system modifications in elderly frail subjects and its relationship with frailty. Subjects with hip fracture and outpatients without fractur
Mini–Mental State Examination (MMSE)
and Mini Nutritional Assessment (MNA). Frailty was measured using SHARE-FI and major osteoporotic and hip risk measured by FRAX Score tool. Comorbidities were assessed using the Cumulative Illness Rat
Sponsors
University of Rome "Tor Vergata"
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients hospitalized in the Orthopedic Department after a hip fracture 2. Control subjects enrolled among outpatients evaluated at the Department of Medicine (Clinical Program on Atherosclerosis) 3. Age over 65 years
Exclusion criteria
Exclusion criteria: Presence of a malignancy or a history of previous cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of endocrine system abnormalities, measured using blood sampling for laboratory assays at baseline (serum cortisol, TSH, free T3 [FT3], free T4 [FT4], IGF-1, GH, DHEAS, PTH, Vitamin D, OPG, OC, interleukin-6 [IL-6] and tumor necrosis factor-a [TNF-a]) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Disability, measured using ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living) at baseline and 1 and 2 years follow-up 2. Cognitive impairment, measured using Mini-Mental State Examination (MMSE) at baseline 3. Nutritional status, measured using Mini Nutritional Assesment (MNA) at baseline and 1 and 2 years follow-up 4. Comorbidities, assessed using Cumulative Illness Rating Scale for Geriatrics (CIRS-G) and Charlson comorbidity index (CCI) at baseline 5. Frailty, measured by SHARE-FI at baseline 6. Major osteoporotic and hip risk, measured by FRAX Score tool at baseline 7. Mortality and recurrence of fracture, measured at 1 and 2 years follow-up | — |
Countries
Italy
Outcome results
None listed